Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Fasching, P; Stechemesser, L; Auer, J; Clodi, M; Gattringer, T; Niessner, A; Perl, S; Saemann, M; Seinost, G; Huber, K.
Practical realization of guidelines for treatment of type 2 diabetes with a high cardiovascular risk
J KARDIOL. 2023; 30(5-6): 119-122.
Web of Science
- Führende Autor*innen der Med Uni Graz
- Fasching Patrizia
- Co-Autor*innen der Med Uni Graz
- Gattringer Thomas
- Perl Sabine
- Seinost Gerald
- Altmetrics:
- Abstract:
- In recent years, GLP-1 receptor-agonists and SGLT2 inhibitors have shown a very high level of evidence and recommendation for the treatment of patients with type-2-diabetes and high cardiovascular risk. These medications were developed for the treatment of hyperglycemia, cardiovascular endpoint studies showed a CV-benefit independent of baseline-HbA1c. In the practical im-plementation of these therapies, however, there are ongoing challenges that need to be identified and overcome - especially for this well described high risk population. J Kardiol 2023; 30 (5-6): 119-22.
- Find related publications in this database (Keywords)
- type-2-diabetes
- high cardiovascular risk
- guidelines
- GLP-1 Receptor-Agonists
- SGLT2 In-hibitors
- CV-benefit